Ascentage Pharma Group International
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Ascentage Pharma Group International.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 14.90 $ to 40.20 $ · Last price: 15.40 $ (As of: September 29, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/29/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Ascentage Pharma Group International AAPG | 1.4 | – | 0.0 | 93.9 | -193.4 | -43.1 | -60.1 |
| Vertex Pharmaceuticals Inc VRTX | 133.2 | 32.0 | 24.4 | 55.0 | 38.1 | 9.6 | 33.2 |
| Moderna Inc MRNA | 80.7 | – | 4.6 | -66.0 | -131.1 | -39.2 | 703.2 |
| Regeneron Pharmaceuticals Inc REGN | 78.0 | 18.9 | 13.5 | 44.5 | 20.7 | 1.0 | 34.1 |
| argenx NV ARGX | 60.4 | 37.1 | 30.7 | 59.1 | 32.0 | 89.6 | 36.6 |
| Revolution Medicines Inc RVMD | 42.5 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 359.3 |
| BeiGene, Ltd. ONC | 41.3 | 65.2 | 33.7 | 88.9 | 19.1 | 40.2 | 12.6 |
| Alnylam Pharmaceuticals Inc ALNY | 33.7 | 63.9 | 28.6 | 79.7 | 23.0 | 65.2 | -42.8 |
| Royalty Pharma Plc RPRX | 32.1 | 31.4 | 19.2 | 95.8 | 100.3 | 5.1 | 68.4 |
| Median of companies shown | 42.5 | 34.5 | 19.2 | 59.1 | 20.7 | 5.1 | 34.1 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year CNY m
Revenue Operating income Net income
| Fiscal Year | Revenue (CNY m) | EBIT (CNY m) | Net Income (CNY m) | EPS (CNY) | Operating Cash Flow (CNY m) | Equity (CNY m) | Total Assets (CNY m) |
|---|---|---|---|---|---|---|---|
| 2016 | 8 | -115 | -108 | -8.33 | -46 | -15 | 593 |
| 2017 | 6 | -131 | -119 | -9.16 | -108 | -132 | 582 |
| 2018 | 7 | -345 | -345 | -26.68 | -238 | -1,012 | 1,229 |
| 2019 | 15 | -583 | -1,481 | -112.02 | -460 | 890 | 1,205 |
| 2020 | 12 | -664 | -678 | -50.21 | -610 | 847 | 1,731 |
| 2021 | 28 | -870 | -782 | -49.17 | -605 | 1,235 | 2,940 |
| 2022 | 210 | -850 | -883 | -53.58 | -654 | 409 | 2,830 |
| 2023 | 222 | -873 | -926 | -52.46 | -726 | 60 | 2,500 |
| 2024 | 981 | -370 | -405 | -5.37 | -111 | 264 | 2,618 |
| 2025 | 558 | -1,179 | -1,209 | -13.58 | -1,174 | 1,325 | 3,966 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales (CNY m) | Sales YoY (%) | Net Margin (%) | OCF (CNY m) | FCF (CNY m) |
|---|---|---|---|---|---|---|---|
| 2023: Q4 | – | – | 79 | -24.40 | -660.00 | -361 | -373 |
| 2024: Q2 | – | – | 824 | 477.30 | 19.80 | -390 | -407 |
| 2024: Q3 | – | – | 79 | 97.90 | -362.30 | 122 | 118 |
| 2024: Q4 | – | – | 157 | 97.90 | -362.30 | 243 | 235 |
| 2025: Q1 | -1.82 | – | 157 | -61.90 | -362.30 | 217 | 210 |
| 2025: Q2 | -1.73 | – | 234 | -71.60 | -252.80 | -453 | -473 |
| 2025: Q4 | – | – | 334 | 113.00 | -191.50 | -780 | -787 |
| 2026: Q1 | 0.00 | 100.00 | 334 | 113.00 | -191.50 | -780 | -787 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate (CNY) | EPS Range (CNY) | Revenue Estimate (CNY m) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.19 | -2.38 – -0.57 | 697 | 40.7% | 3 |
| 12/31/2027 | -1.04 | -2.05 – -0.52 | 1,484 | 12.6% | 3 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 38.6%
- More than 10% revenue growth is expected for the coming year 54.4%
- Share count grows by less than 3% a year 75.5%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -258.2%
- Gross margin at 40% or higher and without meaningful erosion 76.4%
- Goodwill from acquisitions does not grow faster than revenue 0.6%
- Net debt below twice EBITDA 491 m net cash
- Operating cash flow covers the profits of the last three years 528 m
- Return on capital at 15% or higher, or up versus two years ago -50.8%
- Insiders hold at least 10% or are net buyers 0.0%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
5/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 61.0%
- Exp. sales growth 3Y > 5% 63.0%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 63.0%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -97.9%
- ROCE > 15% -50.8%
- Expected return > 10% 42.7%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
The company
About the Company
Ascentage Pharma Group International ist ein klinisches Biotechnologieunternehmen, das Therapien gegen Krebs, chronische Hepatitis-B-Infektion (HBV) und altersbedingte Erkrankungen im chinesischen Kernland entwickelt. Der primäre Produktkandidat des Unternehmens ist HQP1351, ein BCR-ABL-Inhibitor, der auf BCR-ABL1-Mutanten abzielt, einschließlich jener mit der T315I-Mutation. Es entwickelt außerdem APG-2575, einen oral verabreichten selektiven Bcl-2-Inhibitor für hämatologische Malignome und solide Tumoren; APG-115, einen oralen niedermolekularen Inhibitor der MDM2-p53-Protein-Protein-Interaktion zur Behandlung solider Tumoren und hämatologischer Malignome; sowie APG-1252, ein niedermolekulares Medikament zur Wiederherstellung der Apoptose durch duale Hemmung der Proteine Bcl-2 und Bcl-xL zur Behandlung von kleinzelligem Lungenkarzinom, nicht-kleinzelligem Lungenkarzinom, neuroendokrinem Tumor und Non-Hodgkin-Lymphom. Darüber hinaus entwickelt das Unternehmen APG-1387, einen niedermolekularen Inhibitor von Apoptoseproteinen für fortgeschrittene solide Tumoren und chronische HBV-Infektion, sowie APG-5918, einen oral verfügbaren und selektiven Inhibitor der embryonalen Ektodermentwicklung. Zudem ist es in der medizinischen Forschung und Entwicklung, der klinischen Entwicklung, der Durchführung klinischer Studien, Venture-Capital-Investitionen, der Gebäudevermietung sowie der Bereitstellung von Wissenschafts- und Technologieförderdiensten tätig. Das Unternehmen unterhält Kooperationsbeziehungen mit Biotechnologie- und Pharmaunternehmen sowie Forschungseinrichtungen. Ascentage Pharma Group International wurde 2009 gegründet und hat ihren Hauptsitz in Suzhou, China.
- Employees
- 828
- Headquarters
- Suzhou, China
- Address
- Suzhou Industrial Park, 215000 Suzhou, China
- Phone
- 86 512 8555 7777
- Website
- ascentage.cn
- IPO Date
- 01/24/2025
- ISIN
- US04390B1052
Management
| Name | Title | Birth Year |
|---|---|---|
| Dajun Yang M.D., Ph.D. | Co-Founder, Chairman & CEO | 1963 |
| Shaomeng Wang Ph.D. | Co-Founder, Chief Scientific Advisor & Non-Executive Director | 1965 |
| Ming Guo Ph.D. | Co-Founder | 1958 |
| Veet Misra | Chief Financial Officer | – |
| Yuly Chen | Senior Director of Investor Relations | – |
| Thomas Joseph Knapp J.D. | Senior VP & General Counsel | 1953 |
| Yifan Zhai M.D., Ph.D. | Chief Medical Officer | 1963 |
| Chongdong Fu | Senior VP & Head of CMC | – |
| Jin Cao | Head of Finance | 1986 |
| James Ziegler M.B.A. | Chief Commercial Officer | 1966 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.